A total of 263 EBUS-TBNA specimens were evaluated for adequacy with 110 (93.2%) of the squamous cell carcinoma samples and 127 (87.6%) of the adenocarcinoma samples deemed adequate for PD-L1 testing. This evidence concerns the gene CD274 and adenocarcinoma.